Multivalent Pneumococcal Vaccine Serotype Coverage via Polysaccharide-Protein Conjugates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current multivalent pneumococcal vaccines have limitations in serotype coverage, leading to increasing prevalence of pneumococci expressing serotypes not present in existing vaccines, necessitating broader protection against pneumococcal disease.
Innovation Solution
Development of multivalent immunogenic compositions comprising polysaccharide-protein conjugates that include a range of Streptococcus pneumoniae serotypes, such as 1, 3, 4, 5, 6A, 6B, 7F, 9V, 10A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23B, 23F, 24F, 33F, and 35B, conjugated to a carrier protein like CRM197, to provide broader serotype coverage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current multivalent pneumococcal vaccines are used, then serotype coverage is limited to specific strains, but this leads to increasing prevalence of pneumococci expressing serotypes not present in existing vaccines
Solution Approach 1:
The vaccine is divided into multiple serotype-specific polysaccharide components, each conjugated to a carrier protein. This segmentation allows the vaccine to target multiple specific serotypes (including 1, 3, 4, 5, 6A, 6B, 7F, 9V, 10A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23B, 23F, 24F, 33F, and 35B) independently, enabling comprehensive coverage against diverse pneumococcal strains while maintaining immunogenicity for each serotype.
Solution Approach 2:
The vaccine formulation provides multi-functionality by incorporating polysaccharide-protein conjugates from numerous serotypes within a single vaccine product. This universal approach protects against a broad spectrum of pneumococcal serotypes, including emerging strains, thereby enhancing the vaccine's adaptability and protective effectiveness across different pneumococcal variants.
2Adaptability or versatility
If polysaccharide-protein conjugates from multiple serotypes are included, then broader protection is achieved, but the complexity of the vaccine composition increases
Solution Approach 1:
Multiple polysaccharide-protein conjugate components are merged into a single unified vaccine formulation. Each conjugate consists of a specific pneumococcal polysaccharide covalently linked to a carrier protein, and all conjugates are combined in one vaccine product. This merging approach achieves broad serotype coverage while managing complexity through integrated formulation rather than separate administrations.
Solution Approach 2:
The vaccine employs composite material structure by combining polysaccharide antigens with protein carrier molecules to form conjugates. This composite approach leverages the immunogenic properties of both polysaccharides and proteins, creating a synergistic effect that enhances immune response while consolidating multiple serotypes into a single complex but coordinated vaccine composition.
Data Source
AI summary
The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and/or pneumococcal diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.